Tuberculosis (TB) is a growing national and international health concern today. A revision of pharmacological treatment of TB is done in this issue. Regimens for TB disease and latent TB treatment are described. Common adverse reactions and drug interactions of first and second-line antituberculosis drug are summarized in tables. Management strategies to improve treatment adherence and TB control, treat special situations like immunodeficiences, pregnancy, hepatic and renal impairment and multidrug resistant TB are presented. In a next future the prospects for using more effective and shorter new treatments to fight against this disease are not very promising.